149 results on '"McGuire, Darren K."'
Search Results
52. Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials.
- Author
-
Leiter, Lawrence A., Bhatt, Deepak L., McGuire, Darren K., Teoh, Hwee, Fox, Kim, Simon, Tabassome, Mehta, Shamir R., Lev, Eli I., Kiss, Róbert G., Dalby, Anthony J., Bueno, Héctor, Ridderstråle, Wilhelm, Himmelmann, Anders, Prats, Jayne, Liu, Yuyin, Lee, Jane J., Amerena, John, Kosiborod, Mikhail N., Steg, Philippe Gabriel, and THEMIS Steering Committee and Investigators
- Subjects
- *
TYPE 2 diabetes , *ASPIRIN , *TICAGRELOR , *PERCUTANEOUS coronary intervention , *PLATELET aggregation inhibitors , *COMBINATION drug therapy , *CLINICAL trials , *MEDICAL care , *RETROSPECTIVE studies , *CARDIOVASCULAR system , *TREATMENT effectiveness , *CORONARY artery disease , *LONGITUDINAL method , *DISEASE complications - Abstract
Background: THEMIS (The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study) (n = 19,220) and its pre-specified THEMIS-PCI (The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study-Percutaneous Coronary Intervention) (n = 11,154) subanalysis showed, in individuals with type 2 diabetes mellitus (median duration 10.0 years; HbA1c 7.1%) and stable coronary artery disease without prior myocardial infarction (MI) or stroke, that ticagrelor plus aspirin (compared with placebo plus aspirin) produced a favorable net clinical benefit (composite of all-cause mortality, MI, stroke, fatal bleeding, and intracranial bleeding) if the patients had a previous percutaneous coronary intervention.Objectives: In these post hoc analyses, the authors examined whether the primary efficacy outcome (cardiovascular death, MI, stroke: 3-point major adverse cardiovascular events [MACE]), primary safety outcome (Thrombolysis In Myocardial Infarction-defined major bleeding) and net clinical benefit varied with diabetes-related factors.Methods: Outcomes were analyzed across baseline diabetes duration, HbA1c, and antihyperglycemic medications.Results: In THEMIS, the incidence of 3-point MACE increased with diabetes duration (6.7% for ≤5 years, 11.1% for >20 years) and HbA1c (6.4% for ≤6.0%, 11.8% for >10.0%). The relative benefits of ticagrelor plus aspirin on 3-point MACE reduction (hazard ratio [HR]: 0.90; p = 0.04) were generally consistent across subgroups. Major bleeding event rate (overall: 1.6%) did not vary by diabetes duration or HbA1c and was increased similarly by ticagrelor across all subgroups (HR: 2.32; p < 0.001). These findings were mirrored in THEMIS-PCI. The efficacy and safety of ticagrelor plus aspirin did not differ by baseline antihyperglycemic therapy. In THEMIS-PCI, but not THEMIS, ticagrelor generally produced favorable net clinical benefit across diabetes duration, HbA1c, and antihyperglycemic medications.Conclusion: Ticagrelor plus aspirin yielded generally consistent and favorable net clinical benefit across the diabetes-related factors in THEMIS-PCI but not in the overall THEMIS population. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
53. Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.
- Author
-
Bonaca, Marc P., Bhatt, Deepak L., Simon, Tabassome, Fox, Kim Michael, Mehta, Shamir, Harrington, Robert A., Leiter, Lawrence A., Capell, Warren H., Held, Claes, Himmelmann, Anders, Ridderstråle, Wilhelm, Chen, Jersey, Lee, Jane J., Song, Yang, Andersson, Marielle, Prats, Jayne, Kosiborod, Mikhail, McGuire, Darren K., and Steg, Ph. Gabriel
- Subjects
- *
PEOPLE with diabetes , *TYPE 2 diabetes , *DIABETES , *MAJOR adverse cardiovascular events , *TICAGRELOR - Abstract
Ticagrelor reduced major adverse cardiovascular events (MACE) and increased bleeding in patients with type 2 diabetes mellitus (T2DM) and coronary artery disease. Limb events including revascularization, acute limb ischemia (ALI), and amputation are major morbidities in patients with T2DM and atherosclerosis. This study sought to determine the effect of ticagrelor on limb events. Patients were randomized to ticagrelor or placebo on top of aspirin and followed for a median of 3 years. MACE (cardiovascular death, myocardial infarction, or stroke), limb events (ALI, amputation, revascularization), and bleeding were adjudicated by an independent and blinded clinical events committee. The presence of peripheral artery disease (PAD) was reported at baseline. Of 19,220 patients randomized, 1,687 (8.8%) had PAD at baseline. In patients receiving placebo, PAD was associated with higher MACE (10.7% vs 7.3%; HR: 1.48; P < 0.001) and limb (9.5% vs 0.8%; HR: 10.67; P < 0.001) risk. Ticagrelor reduced limb events (1.6% vs 1.3%; HR: 0.77; 95% CI: 0.61-0.96; P = 0.022) with significant reductions for revascularization (HR: 0.79; 95% CI: 0.62-0.99; P = 0.044) and ALI (HR: 0.24; 95% CI: 0.08-0.70; P = 0.009). The benefit was consistent with or without PAD (HR: 0.80; 95% CI: 0.58-1.11; and HR: 0.76; 95% CI: 0.55-1.05, respectively; P interaction = 0.81). There was no effect modification of ticagrelor vs placebo based on PAD for MACE (P interaction = 0.40) or TIMI major bleeding (P interaction = 0.3239). Patients with T2DM and atherosclerosis are at high risk of limb events. Ticagrelor decreased this risk, but increased bleeding. Future trials evaluating the combination of ticagrelor and aspirin would further elucidate the benefit/risk of such therapy in patients with PAD, including those without coronary artery disease. (A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus [THEMIS]: NCT01991795) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
54. Vascular Regenerative Cell Deficiencies in South Asian Adults.
- Author
-
Krishnaraj, Aishwarya, Bakbak, Ehab, Teoh, Hwee, Pan, Yi, Firoz, Irene N., Pandey, Arjun K., Terenzi, Daniella C., Verma, Raj, Bari, Basel, Bakbak, Asaad I., Kunjummar, Shakkeela Padanilathu, Yanagawa, Bobby, Connelly, Kim A., Mazer, C. David, Rotstein, Ori D., Quan, Adrian, Bhatt, Deepak L., McGuire, Darren K., Hess, David A., and Verma, Subodh
- Subjects
- *
SOUTH Asians , *ASIANS , *ALDEHYDE dehydrogenase , *PROGENITOR cells , *GLYCOSYLATED hemoglobin - Abstract
South Asian individuals shoulder a disproportionate burden of cardiometabolic diseases. The purpose of this study was to determine if vascular regenerative cell content varies significantly between South Asian and White European people. Between January 2022 and January 2023, 60 South Asian and 60 White European adults with either documented cardiovascular disease or established diabetes with ≥1 other cardiovascular risk factor were prospectively enrolled. Vascular regenerative cell content in venous blood was enumerated using a flow cytometry assay that is based on high aldehyde dehydrogenase (ALDHhi) activity and cell surface marker phenotyping. The primary outcome was the difference in frequency of circulating ALDHhi progenitor cells, monocytes, and granulocytes between the 2 groups. Compared with White European participants, those of South Asian ethnicity were younger (69 ± 10 years vs 66 ± 9 years; P < 0.05), had lower weight (88 ± 19 kg vs 75 ± 13 kg; P < 0.001), and exhibited a greater prevalence of type 2 diabetes (62% vs 92%). South Asian individuals had markedly lower circulating frequencies of pro-angiogenic ALDHhiSSClowCD133+ progenitor cells (P < 0.001) and ALDHhiSSCmidCD14+CD163+ monocytes with vessel-reparative capacity (P < 0.001), as well as proportionally more ALDHhi progenitor cells with high reactive oxygen species content (P < 0.05). After correction for sex, age, body mass index, and glycated hemoglobin, South Asian ethnicity was independently associated with lower ALDHhiSSClowCD133+ cell count. South Asian people with cardiometabolic disease had less vascular regenerative and reparative cells suggesting compromised vessel repair capabilities that may contribute to the excess vascular risk in this population. (The Role of South Asian vs European Origins on Circulating Regenerative Cell Exhaustion [ORIGINS-RCE]; NCT05253521) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
55. 17 - Cardiovascular Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs. Insulin Glargine U100 in Older Patients (≥65 Years) with Type 2 Diabetes: Observations From DEVOTE.
- Author
-
Pratley, Richard E., Emerson, Scott S., Franek, Edward, Gilbert, Matthew P., Marso, Steven P., McGuire, Darren K., Pieber, Thomas R., Poulter, Neil R., Hansen, Charlotte T., Hansen, Melissa V., Mark, Thomas, Moses, Alan C., Zinman, Bernard, and Hahn, Jina
- Published
- 2018
- Full Text
- View/download PDF
56. The association between HDL particle concentration and incident metabolic syndrome in the multi-ethnic Dallas Heart Study.
- Author
-
Mani, Preethi, Ren, Hao-Yu, Neeland, Ian J., McGuire, Darren K., Ayers, Colby R., Khera, Amit, and Rohatgi, Anand
- Abstract
Aims Metabolic syndrome (MetS) increases atherosclerotic cardiovascular disease (ASCVD) risk. Low HDL cholesterol (HDL-C) is a diagnostic criterion of MetS and a major ASCVD risk factor. HDL particle concentration (HDL-P) associates with incident ASCVD independent of HDL-C, but its association with incident MetS has not been studied. We hypothesized that HDL-P would be inversely associated with incident metabolic syndrome independent of HDL-C and markers of adiposity and insulin resistance. Materials and methods HDL-P was measured by NMR and visceral fat by MRI in participants of the Dallas Heart Study, a probability-based population sample of adults age 30–65. Participants with prevalent MetS, DM, CVD, and any systemic illlness were excluded. Incident MetS as defined by NCEP ATPIII criteria was determined in all participants after median follow-up period of 7.0 years. Results Among 1120 participants without DM or MetS at baseline (57% women, 45% Black, mean age 43), 22.8% had incident MetS at follow-up. HDL-P and HDL-C were modestly correlated (r = 0.54, p < 0.0001). In models adjusted for traditional risk factors and MetS risk factors including visceral fat, HS-CRP, triglyceride to HDL-C ratio, and HOMA-IR, the lowest quartile of HDL-P was associated with a 2-fold increased risk of incident MetS (OR 2.1, 95%CI 1.4–3.1; p = 0.0003). Conclusions Low HDL-P is independently associated with incident MetS after adjustment for traditional risk factors, lipid parameters, adiposity, inflammation, and markers of insulin resistance. Further studies are warranted to validate these findings and elucidate the mechanisms underpinning this association. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
57. Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.
- Author
-
Aggarwal, Rahul, Bhatt, Deepak L., Szarek, Michael, Cannon, Christopher P., McGuire, Darren K., Inzucchi, Silvio E., Lopes, Renato D., Davies, Michael J., Banks, Phillip, Pitt, Bertram, and Steg, Philippe Gabriel
- Subjects
- *
TYPE 2 diabetes , *GLYCOSYLATED hemoglobin , *PROPORTIONAL hazards models , *HEMOGLOBINS , *ADULTS - Abstract
The SCORED (Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) and SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) trials demonstrated that sotagliflozin, an SGLT1 and SGLT2 inhibitor, improves outcomes in individuals with type 2 diabetes who have heart failure (HF) or kidney disease. We assessed the efficacy of sotagliflozin on HF clinical outcomes in individuals with differing baseline glycosylated hemoglobin (HbA1c) levels. We included all adults from SCORED and SOLOIST-WHF. The primary outcome was a composite of cardiovascular death, hospitalizations for HF, and urgent visits for HF. The efficacy of sotagliflozin compared with placebo was evaluated by baseline HbA1c using competing-risk marginal proportional hazards models. We identified 11,744 adults. Individuals with HbA1c ≤7.5% experienced the primary outcome at a lower rate in the sotagliflozin group (11.2 per 100 person-years) than the placebo group (15.5 per 100 person-years) (HR: 0.73; 95% CI: 0.57-0.93). Similarly, individuals with HbA1c of 7.6% to 9.0% experienced the primary outcome at a lower rate in the sotagliflozin group (7.3 per 100 person-years) than the placebo group (9.4 per 100 person-years) (HR: 0.77; 95% CI: 0.63-0.96). These findings were also consistent among individuals with HbA1c >9.0%, with a primary outcome rate in the sotagliflozin group (7.8 per 100 person-years) that was lower than the placebo group (11.6 per 100 person-years) (HR: 0.65; 95% CI: 0.50-0.84). The efficacy of sotagliflozin was consistent by baseline HbA1c level (P for interaction = 0.58). In individuals with type 2 diabetes and either HF or kidney disease, sotagliflozin reduced HF outcomes irrespective of baseline HbA1c. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
58. Interview with Dr. Scott Grundy during AHA EPI/NPAM Meeting in March 2011.
- Author
-
McGuire, Darren K. and Grundy, Scott M.
- Published
- 2011
- Full Text
- View/download PDF
59. Nesiritide in acute heart failure.
- Author
-
Drazner, Mark, McGuire, Darren K, and de Lemos, James A
- Published
- 2003
- Full Text
- View/download PDF
60. Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial.
- Author
-
Arnold, Suzanne V., McGuire, Darren K., Spertus, John A., Tang, Fengming, Yue, Patrick, Inzucchi, Silvio E., Belardinelli, Luiz, Chaitman, Bernard R., and Kosiborod, Mikhail
- Abstract
Background: Different classes of glucose-lowering medications have been associated with varying risks of myocardial infarction and cardiovascular death, but their effect on angina is unknown. Therefore, we sought to determine the association of different glucose-lowering medication classes with angina frequency and nitroglycerin (NTG) use.Methods: We performed a secondary, observational analysis of the TERISA multinational trial, which evaluated the antianginal effect of ranolazine versus placebo in patients with type 2 diabetes mellitus, documented coronary disease, and a 3-month history of stable angina. Patients recorded angina and NTG use in a daily dairy for 3 weeks prior to randomization, to establish their baseline angina burden for the trial. We then examined the association of different glucose-lowering medication classes with baseline angina and NTG use using multivariable linear regression.Results: Among 952 patients enrolled, 494 were taking metformin, 504 taking a sulfonylurea, 186 taking insulin, 29 taking DPP-4 inhibitors, 22 taking other glucose-lowering medications, and 68 were diet-controlled only. After adjustment for demographic and clinical factors, patients taking versus not taking sulfonylureas had 1.02 more episodes of angina and used 0.93 more doses of NTG per week (P = .002 and .011, respectively). The weekly angina burden or NTG use was not different for those taking versus not taking metformin (P > .7 for both). Patients taking versus not taking insulin had 0.83 more episodes of angina and used 1.40 more NTG doses per week, increases evident only in those taking insulin without concomitant metformin (Pinteraction < .05 for both).Conclusion: Different classes of glucose-lowering medications were associated with varying angina burden in patients with type 2 diabetes mellitus and stable coronary disease. Patients taking sulfonylureas or insulin had more angina and used more NTG, while metformin was not associated with angina burden. Given the increasing prevalence of glucose abnormalities in patients with coronary disease, a better understanding of the relationship between glucose-lowering medications and angina is needed. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
61. Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage...
- Author
-
Clemmensen, Peter, Roe, Matthew T., Hochman, Judith S., Cyr, Derek D., Neely, Megan L., McGuire, Darren K., Cornel, Jan H., Huber, Kurt, Zamoryakhin, Dmitry, White, Harvey D., Armstrong, Paul W., Fox, Keith A.A., Prabhakaran, Dorairaj, Ohman, Erik Magnus, and TRILOGY ACS Investigators
- Abstract
Background: Women with acute coronary syndromes (ACS) are less likely to undergo invasive revascularization than men, but sex-specific differences in long-term outcomes and platelet reactivity among medically managed ACS patients remain uncertain. We examined sex-specific differences in long-term ischemic and bleeding outcomes and platelet reactivity for medically managed ACS patients randomized to prasugrel versus clopidogrel plus aspirin.Methods: Data from 9,326 patients enrolled in TRILOGY ACS were analyzed to determine differences in long-term ischemic and bleeding outcomes between women (n = 3,650 [39%]) and men (n = 5,676 [61%]) randomized to prasugrel 10 mg/d (5 mg/d for patients ≥75 years and/or <60 kg) versus clopidogrel 75 mg/d. Sex-specific differences in 30-day platelet reactivity were analyzed in 2,564 (27%) patients participating in a platelet function substudy.Results: Compared with men, women were older, weighed less, were less likely to have prior myocardial infarction or revascularization, and had lower baseline creatinine clearance and hemoglobin level values. Rates of the composite of cardiovascular death/myocardial infarction/stroke (20.2% vs 19.1%; P = .56), all-cause mortality (12.2% vs 11.7%; P = .88), and Global Use of Strategies to Open Occluded Arteries severe/life-threatening/moderate bleeding (3.8% vs 2.8%; P = .74) through 30 months were similar in women versus men. After adjustment, women had significantly lower risk for ischemic outcomes and all-cause mortality. There were no sex-specific, treatment-related differences in 30-day platelet reactivity.Conclusions: Long-term ischemic and bleeding outcomes in medically managed ACS patients were similar for women versus men, as was treatment-related platelet reactivity. Women had a higher baseline risk profile and, after adjustment, significantly lower risk of the primary composite end point and all-cause death through 30 months. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
62. Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.
- Author
-
Arnold, Suzanne V., McGuire, Darren K., Spertus, John A., Li, Yan, Yue, Patrick, Ben-Yehuda, Ori, Belardinelli, Luiz, Jones, Philip G., Olmsted, Ann, Chaitman, Bernard R., and Kosiborod, Mikhail
- Abstract
Background Ranolazine reduces the frequency of angina and use of sublingual nitroglycerin (SL NTG) in stable angina patients with type 2 diabetes (T2DM). Because pre-clinical data suggest that myocardial late sodium current (I NaL ), the target of ranolazine, is increased by hyperglycemia, we investigated whether the efficacy of ranolazine was influenced by glycemic control. Methods TERISA was a multinational, randomized, double-blind trial of ranolazine vs. placebo in patients with T2DM and stable angina. Anginal episodes and SL NTG use were recorded daily in an electronic diary. Health status was evaluated at baseline and 8 weeks post-randomization using the Seattle Angina Questionnaire (SAQ). The interaction between baseline HbA 1c and treatment effect was tested across endpoints using analysis of covariance models, with HbA 1c as a continuous variable with restricted cubic splines. Results The study included 913 patients, with mean age 63.6 years, 39% women, mean T2DM duration 7.4 years, and mean HbA 1c of 7.3%. Heterogeneity of efficacy by HbA 1c was observed for the primary endpoint of angina frequency ( P interaction = .027), the key secondary endpoint of SL NTG use ( P interaction = .030), SAQ angina frequency ( P interaction = .001), and SAQ treatment satisfaction ( P interaction = .025) with greater efficacy of ranolazine in those with higher HbA 1c values, increasing continuously from HbA 1c levels >6.5%. Conclusion Among patients with T2DM and stable angina, the therapeutic benefits of ranolazine were greater in those with higher HbA 1c values. These data suggest that ranolazine is particularly beneficial in patients with stable angina who have suboptimally controlled T2DM. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
63. Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction.
- Author
-
Arnold, Suzanne V., Lipska, Kasia J., Li, Yan, McGuire, Darren K., Goyal, Abhinav, Spertus, John A., and Kosiborod, Mikhail
- Abstract
Background Patients with an acute myocardial infarction (AMI) who have glucose abnormalities are at increased risk for death and adverse ischemic outcomes. The contemporary prevalence of glucose abnormalities among AMI patients in the United States, as determined by hemoglobin A1c (HbA1c), is unknown. Methods Patients hospitalized with AMI in a 24-site US AMI registry from 2005 to 2008 were examined for the presence of dysglycemia using HbA1c, which was analyzed at a core laboratory. Patients were categorized by American Diabetes Association guidelines as having diabetes (HbA1c ≥ 6.5%), prediabetes (HbA1c 5.7%-6.4%), or normoglycemia. Baseline demographic, clinical, and metabolic characteristics, as well as long-term all-cause mortality, were compared among groups. Results Among 2,853 patients with AMI, 1,083 (38%) had diabetes, of which 196 (18%) were newly diagnosed. There were an additional 887 patients (31%) with prediabetes and 883 patients (31%) who had normal glucose metabolism. Patients with metabolic abnormalities were older, were more frequently female, and had higher prevalence of cardiac and noncardiac comorbidities, including multivessel disease and left ventricular systolic dysfunction. Patients with increasing metabolic abnormalities had higher mortality over the 3 years after the AMI (8.6% in those with normoglycemia, 10.6% in prediabetes, 11.3% in newly diagnosed diabetes, and 20.3% in known diabetes; log rank P < .001). Conclusions In a large US AMI registry, we found that nearly 7 in 10 patients had dysglycemia, with 38% having diabetes and an additional 31% with prediabetes based on HbA1c levels. Over half of the patients who did not have a known diagnosis of diabetes at the time of admission had either newly diagnosed diabetes or prediabetes. Progressively greater severity of dysglycemia was also associated with incremental increase in long-term mortality. These data highlight the AMI hospitalization as a key opportunity to screen for glucose abnormalities so that appropriate interventions and patient education efforts can be implemented prior to discharge. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
64. Type of β-blocker use among patients with versus without diabetes after myocardial infarction.
- Author
-
Arnold, Suzanne V., Spertus, John A., Lipska, Kasia J., Lanfear, David E., Tang, Fengming, Grodzinsky, Anna, McGuire, Darren K., Gore, M. Odette, Goyal, Abhinav, Maddox, Thomas M., and Kosiborod, Mikhail
- Abstract
Background Discharge β-blocker prescription after myocardial infarction (MI) is recommended for all eligible patients. Numerous β-blocker choices are presently available with variable glycometabolic effects, which could be an important consideration in patients with diabetes mellitus (DM). Whether patients with DM preferentially receive β-blockers with favorable metabolic effects after MI and if this choice is associated with better glycemic control postdischarge is unknown. Methods Among patients from 24 US hospitals enrolled in an MI registry (2005-2008), we investigated the frequency of “DM-friendly” β-blocker prescription at discharge by DM status. β-Blockers were classified as DM-friendly (eg, carvedilol and labetalol) or non–DM-friendly (eg, metoprolol and atenolol), based on their effects on glycemic control. Hierarchical, multivariable logistic regression examined the association of DM with DM-friendly β-blocker use. Among DM patients, we examined the association of DM-friendly β-blockers with worsened glycemic control at 6 months after MI. Results Of 4,031 MI patients, 1,382 (34%) had DM. β-Blockers were prescribed at discharge in 93% of patients. Diabetes mellitus–friendly β-blocker use was low regardless of DM status, although patients with DM were more likely to be discharged on a DM-friendly β-blocker compared with patients without DM (13.5% vs 10.3%, P = .003), an association that remained after multivariable adjustment (odds ratio 1.41, 95% CI 1.13-1.77). There was a trend toward a lower risk of worsened glucose control at 6 months in DM patients prescribed DM-friendly versus non–DM-friendly β-blockers (Relative Risk 0.80, 95% CI 0.60-1.08). Conclusion Most DM patients were prescribed non–DM-friendly β-blockers—a practice that was associated with a trend toward worse glycemic control postdischarge. Although in need of further confirmation in larger studies, our findings highlight an opportunity to improve current practices of β-blockers use in patients with DM. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
65. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
- Author
-
Usman, Muhammad Shariq, Siddiqi, Tariq Jamal, Anker, Stefan D., Bakris, George L., Bhatt, Deepak L., Filippatos, Gerasimos, Fonarow, Gregg C., Greene, Stephen J., Januzzi, James L., Khan, Muhammad Shahzeb, Kosiborod, Mikhail N., McGuire, Darren K., Piña, Ileana L., Rosenstock, Julio, Vaduganathan, Muthiah, Verma, Subodh, Zieroth, Shelley, and Butler, Javed
- Subjects
- *
SODIUM-glucose cotransporter 2 inhibitors , *IVABRADINE , *ALDOSTERONE antagonists , *TYPE 2 diabetes , *CHRONIC kidney failure - Abstract
The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on heart failure (HF) outcomes and cardiovascular (CV) death in patients with varying combinations of type 2 diabetes mellitus (T2DM), HF, and chronic kidney disease (CKD) are uncertain. The authors conducted a meta-analysis assessing the effects of SGLT2 inhibitors on HF outcomes and CV death across different patient populations. Online databases were queried up to November 2022 for primary and secondary analyses of trials of SGLT2 inhibitors in patients with HF, T2DM, or CKD. Outcomes of interest were composite of first heart failure hospitalization (HFH) or CV death (first HFH/CV death), first HFH, and CV death. Data were pooled by means of a random-effects model to derive HRs and 95% CIs. Thirteen trials (n = 90,413) were included. Compared with placebo, SGLT2 inhibitors reduced the risk of first HFH/CV death by 24% in HF (HR: 0.76; 95% CI: 0.72-0.81), 23% in T2DM (HR: 0.77; 95% CI: 0.73-0.81), and 23% in CKD (HR: 0.77; 95% CI: 0.72-0.82). The benefit was consistent in HF with reduced or preserved ejection fraction, HF with or without T2DM, and HF with or without CKD. The benefit was also consistent in T2DM with or without CKD, T2DM without HF, CKD without HF, and in patients with all 3 comorbidities. SGLT2 inhibitors significantly reduced CV death by 16% in HF, 15% in T2DM, and 12% in CKD. SGLT2 inhibitors reduce HF events and CV death in cohorts of HF, T2DM and CKD, and these effects appear consistent in patients with varying combinations of these diseases. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
66. Temporal trends and hospital variation in the management of severe hyperglycemia among patients with acute myocardial infarction in the United States.
- Author
-
Venkitachalam, Lakshmi, McGuire, Darren K., Gosch, Kensey, Lipska, Kasia, Inzucchi, Silvio E., Lind, Marcus, Goyal, Abhinav, Spertus, John A., Masoudi, Frederick A., Jones, Philip G., and Kosiborod, Mikhail
- Abstract
Background: Elevated blood glucose is associated with higher mortality in patients with acute myocardial infarction (AMI). Although clinical guidelines recommend targeted glucose control in this group, clinical trials have yielded inconclusive results. Our objective was to understand how this lack of evidence impacts the management of severe hyperglycemia in routine practice. Methods: We examined insulin use among 4,297 AMI admissions with a mean hospitalization blood glucose of ≥200 mg/dL across 55 US hospitals from 2000 to 2008. Temporal trends and interhospital variation in 2 measures of insulin use during hospitalization—any (subcutaneous, intravenous [IV], short acting, long acting) and IV insulin—were examined using hierarchical Poisson regression models. Results: Of the 4,297 admissions, 2,618 (61%) received any insulin and 538 (13%) received IV insulin. After multivariable adjustment, a slight increase in insulin use was observed per admission year (relative risk [RR] 1.06, 95% CI 1.01-1.11). There was a modest (albeit nonsignificant) increase in IV insulin use seen before May 2004 (RR 1.18, 95% CI 0.96-1.47), with no significant change thereafter (RR 0.99, 95% CI 0.92-1.09). Marked variability in insulin use was observed across hospitals (median rate ratio 1.5 [any insulin] and 1.8 [IV insulin]), which did not change over time. Conclusions: Insulin use among patients with AMI and severe hyperglycemia has remained low over the past decade, with substantial and persistent interhospital variation. These observations reflect marked clinical uncertainty with regard to glucose management in AMI, underscoring the imperative for a definitive clinical trial in this field. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
67. HEART FAILURE OUTCOMES CAPTURED BY ADVERSE EVENT REPORTING IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL.
- Author
-
Pandey, Ambarish, Kolkailah, Ahmed A., McGuire, Darren K., Frederich, Robert, Cater, Nilo B., Cosentino, Francesco, Liu, Jie, Pratley, Richard, Dagogo-Jack, Samuel, Cherney, David Z.I., Wynant, Willy, Mancuso, James, Masiukiewicz, Urszula, and Cannon, Christopher P.
- Subjects
- *
TYPE 2 diabetes , *HEART failure , *CARDIOVASCULAR diseases - Published
- 2023
- Full Text
- View/download PDF
68. No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction.
- Author
-
Britton, Kathryn A., Aggarwal, Vikas, Chen, Anita Y., Alexander, Karen P., Amsterdam, Ezra, Fraulo, Elizabeth, Muntner, Paul, Thomas, Laine, McGuire, Darren K., Wiviott, Stephen D., Roe, Matthew T., Schubart, Ulrich K., and Fox, Caroline S.
- Abstract
Background: Patients with diabetes have increased in-hospital mortality following acute myocardial infarction (AMI), with studies suggesting higher risk with both hypoglycemia and hyperglycemia. We assessed whether a J-shaped relation exists between hemoglobin A1c (A1C) in patients with diabetes and AMI. Methods: We assessed the associations between A1C and in-hospital mortality using data from a nationwide sample of AMI patients who had both prior diabetes and measurement of A1C (N = 15,337). Results: When evaluated continuously, we observed no evidence of a J-shaped relation between A1C and in-hospital mortality in multivariable analysis (test for linearity P = .89). Patients with lowest (<5.5%) and highest A1C (≥9.5%) had a crude mortality rate of 4.6% and 2.8%, respectively, compared with 3.8% among those in the referent A1C category (6.5% to <7%). In multivariable regression, we observed no association between low A1C (<5.5%, odds ratio 0.81, 95% CI 0.47-1.39) or high A1C (A1C ≥9.5, odds ratio 1.31, 95% CI 0.94-1.83) and mortality as compared with the referent group. These findings can only be generalized to the subset of patients with diabetes who had A1C assessed during their hospitalization; these patients tended to be healthier than those in whom A1C was not assessed. Conclusion: In this large contemporary cohort of patients with diabetes presenting with AMI, we did not observe a J-shaped association between A1C and mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
69. Metformin therapy in patients with Type 2 diabetes complicated by heart failure.
- Author
-
Inzucchi, Silvio E., Masoudi, Frederick A., and McGuire, Darren K.
- Published
- 2007
- Full Text
- View/download PDF
70. Preventing Macrovascular Complications in Type 2 Diabetes Mellitus: Glucose Control and Beyond
- Author
-
Stancoven, Amy and McGuire, Darren K.
- Subjects
- *
DIABETES complications , *TYPE 2 diabetes , *ANTICHOLESTEREMIC agents , *NONSTEROIDAL anti-inflammatory agents - Abstract
Patients with type 2 diabetes mellitus are at increased risk for macrovascular disease complications. Hyperglycemia and atherosclerotic disease clearly are associated, and biologic intermediates mediated by hyperglycemia exist. Our understanding of the pathobiology linking hyperglycemia and atherosclerotic disease continues to evolve. Modulation of the advanced glycation end product (AGE) receptor for AGE (RAGE)/soluble RAGE (sRAGE) system, the thromboxane receptor, and C-peptide comprise just a few of the plausible links between dysglycemia and atherosclerosis. It seems intuitive, therefore, that therapeutic management of blood glucose in patients with diabetes should reduce macrovascular disease and related deaths. However, studies of glucose-lowering therapies performed to date yield qualitatively and quantitatively different results. No definitive proof of the concept is yet available, although it remains probable, with investigations presently under way. Numerous interventions extending beyond glucose control, including lifestyle modification, pharmacologic therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), aspirin, and angiotensin-converting enzyme inhibitors, as well as aggressive blood pressure control independent of blood pressure levels, have proved to be of cardiovascular benefit in the high-risk population of patients with diabetes. Thus, all of these interventions should be used in addition to glucose management in all patients with diabetes who are at increased risk for cardiovascular disease. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
71. 827-3 Women with diabetes mellitus have the greatest reduction in myocardial infarction mortality over the past decade: Evaluation of 1,428,596 patients enrolled in the national registry of myocardial infarction 2, 3, and 4 from 1994–2002.
- Author
-
McGuire, Darren K, Khera, Amit, de Lemos, James A, Peterson, Eric D, Warner, John J, Parsons, Lori S, Rogers, William J, Canto, John G, and National Registry of Myocardial Infarctions Investigators, null
- Subjects
- *
MYOCARDIAL infarction , *DIABETES in women , *ECHOCARDIOGRAPHY , *DEATH rate , *PATIENTS ,MYOCARDIAL infarction-related mortality - Published
- 2004
- Full Text
- View/download PDF
72. Diabetes-related knowledge is not associated with measures of risk factor control in patients with diabetes and acute coronary syndromes
- Author
-
Sanchez, Carlos D., McGuire, Darren K., Newby, L. Kristin, Hasselblad, Vic, Feinglos, Mark N., and Ohman, E. Magnus
- Published
- 2002
- Full Text
- View/download PDF
73. Diabetes is associated with a higher risk of death than is prior myocardial infarction in the setting of coronary disease: results from the Duke cardiovascular database
- Author
-
McGuire, Darren K., Rao, Sunil V., Joski, Peter J., Barsness, Gregory W., Peterson, Eric D., Jollis, James G., Feinglos, Mark N., and Granger, Christopher B.
- Published
- 2002
- Full Text
- View/download PDF
74. Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison.
- Author
-
Kelsey, Michelle D., Nelson, Adam J., Green, Jennifer B., Granger, Christopher B., Peterson, Eric D., McGuire, Darren K., and Pagidipati, Neha J.
- Subjects
- *
TYPE 2 diabetes , *CARDIOVASCULAR diseases risk factors , *GLUCAGON-like peptide-1 receptor , *CARDIOVASCULAR diseases , *DYSLIPIDEMIA , *GLUCAGON-like peptide-1 agonists , *GLYCEMIC control - Abstract
Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor management, with blood pressure and low-density lipoprotein-cholesterol treatment, glycemic control, kidney protection, and lifestyle intervention. There are several recommendation and guideline documents across cardiology, endocrinology, nephrology, and general medicine professional societies from the United States and Europe with recommendations for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Although there are some noteworthy differences, particularly in risk stratification, low-density lipoprotein-cholesterol and blood pressure treatment targets, and the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, overall there is considerable alignment across recommendations from different professional societies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
75. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: Observations from the Dallas Heart Study
- Author
-
Brilakis, Emmanouil S., Khera, Amit, McGuire, Darren K., See, Raphael, Banerjee, Subhash, Murphy, Sabina A., and de Lemos, James A.
- Subjects
- *
MULTICULTURALISM , *ISOPENTENOIDS , *C-reactive protein ,SEX differences (Biology) - Abstract
Abstract: Aims: Most lipoprotein-associated phospholipase A2 (Lp-PLA2) studies included mainly white men. We sought to determine whether Lp-PLA2 levels differ according to race and sex. Methods: Lp-PLA2 mass and activity were measured in 3332 subjects age 30–65 participating in the Dallas Heart Study, a multiethnic, population-based, probability sample. Lp-PLA2 levels were compared between different race and sex groups. Results: Mean age was 45±9 years and 44% were men; 30% were white, 17% hispanic, and 53% black. Mean Lp-PLA2 activity and mass were 146±40nmol/min/mL and 191±60ng/mL, respectively. Lp-PLA2 activity was lower in women compared with men (134±35 vs. 161±40, p =0.001) and was lowest in black (136±38), intermediate in hispanic (151±36), and highest in white subjects (161±39) (trend p =0.0001). In multivariable linear regression models, after adjusting for age, body mass index (BMI), smoking, total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, triglycerides and high sensitivity C-reactive protein (hsCRP), Lp-PLA2 activity was 19nmol/min/mL higher in men vs. women (p <0.001); compared with black subjects, adjusted Lp-PLA2 activity was 11 and 20nmol/min/mL higher in white and hispanic subjects, respectively (both p <0.001). Similar race and sex differences were observed for Lp-PLA2 mass. Conclusion: Race and sex independently influence Lp-PLA2 activity and mass. Thresholds to define Lp-PLA2 elevation may need to be sex and race specific. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
76. The Association of Differing Measures of Overweight and Obesity With Prevalent Atherosclerosis: The Dallas Heart Study
- Author
-
See, Raphael, Abdullah, Shuaib M., McGuire, Darren K., Khera, Amit, Patel, Mahesh J., Lindsey, Jason B., Grundy, Scott M., and de Lemos, James A.
- Subjects
- *
OBESITY , *OVERWEIGHT persons , *ATHEROSCLEROSIS , *MAGNETIC resonance imaging - Abstract
Objectives: This study sought to evaluate the associations between different measures of obesity and prevalent atherosclerosis in a large population-based cohort. Background: Although obesity is associated with cardiovascular mortality, it is unclear whether this relationship is mediated by increased atherosclerotic burden. Methods: Using data from the Dallas Heart Study, we assessed the association between gender-specific obesity measures (i.e., body mass index [BMI]; waist circumference [WC]; waist-to-hip ratio [WHR]) and prevalent atherosclerosis defined as coronary artery calcium (CAC) score >10 Agatston units measured by electron-beam computed tomography and detectable aortic plaque measured by magnetic resonance imaging. Results: In univariable analyses (n = 2,744), CAC prevalence was significantly greater only in the fifth versus first quintile of BMI, whereas it increased stepwise across quintiles of WC and WHR (p trend <0.001 for each). After multivariable adjustment for standard risk factors, prevalent CAC was more frequent in the fifth versus first quintile of WHR (odds ratio 1.91, 95% confidence interval 1.30 to 2.80), whereas no independent positive association was observed for BMI or WC. Similar results were observed for aortic plaque in both univariable and multivariable-adjusted analyses. The c-statistic for discrimination of prevalent CAC was greater for WHR compared with BMI and WC in women and men (p < 0.001 vs. BMI; p < 0.01 vs. WC). Conclusions: We discovered that WHR was independently associated with prevalent atherosclerosis and provided better discrimination than either BMI or WC. The associations between obesity measurements and atherosclerosis mirror those observed between obesity and cardiovascular mortality, suggesting that obesity contributes to cardiovascular mortality via increased atherosclerotic burden. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
77. Coronary artery calcium score, risk factors, and incident coronary heart disease events
- Author
-
Church, Timothy S., Levine, Benjamin D., McGuire, Darren K., LaMonte, Michael J., FitzGerald, Shannon J., Cheng, Yiling J., Kimball, Thomas E., Blair, Steven N., Gibbons, Larry W., and Nichaman, Milton Z.
- Subjects
- *
CORONARY arteries , *CALCIUM , *CORONARY disease , *TOMOGRAPHY - Abstract
Abstract: Background: Whether the absence of coronary artery calcium, or conversely the presence of high volumes of coronary artery calcium, may alter assessment of coronary heart disease risk based on traditional risk factors is uncertain. We sought to identify a potential threshold of coronary artery calcium for clinical use and examine the predictive power of coronary artery calcium in individuals categorized using conventional coronary heart disease risk assessment. Methods: The study included 10,746 men and women (36.3%) with a mean age of 53.8±9.9 years who were either physician- or self-referred for electron beam tomography scanning to a preventive medical clinic. Coronary heart disease risk factors were elicited by use of a questionnaire. Results: During a mean follow-up of 3.5 years, 81 primary events (coronary heart disease death or nonfatal myocardial infarction) occurred. Among individuals with a coronary artery calcium score of zero, the primary event rate was very low (0.4 events per 1000 person-years of observation). When participants were stratified by self-reported coronary heart disease risk factors (0–2, or 3–4), a coronary artery calcium score ≥100 was associated with substantially increased risk of coronary heart disease events within each level of stratification. In a subgroup of participants with available clinical data, similar results were found when participants were categorized by Framingham risk scores. Conclusions: Coronary artery calcium score can identify individuals at increased risk for coronary heart disease events who otherwise would be considered low-risk based on clinical assessment. A coronary artery calcium score of zero is associated with very low risk for coronary heart disease in the short to intermediate term (≈3.5 years) regardless of the number of risk factors present. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
78. The Editor’s Roundtable: Diabetes Mellitus and Coronary Heart Disease
- Author
-
Friedewald, Vincent E., Leiter, Lawrence A., McGuire, Darren K., Nesto, Richard W., and Roberts, William C.
- Published
- 2006
- Full Text
- View/download PDF
79. Diabetes-Related Knowledge, Atherosclerotic Risk Factor Control, and Outcomes in Acute Coronary Syndromes
- Author
-
Sánchez, Carlos D., Newby, L. Kristin, McGuire, Darren K., Hasselblad, Vic, Feinglos, Mark N., and Ohman, E. Magnus
- Subjects
- *
DIABETES , *ENDOCRINE diseases , *DIABETES complications , *ISOPENTENOIDS - Abstract
Patients who have diabetes mellitus have 2 times the incidence of an acute coronary syndrome (ACS) and 2 times the mortality rate after ACS compared with patients who do not have diabetes. Poor patient understanding of diabetes is believed to impede appropriate self-management, thus accelerating cardiovascular complications. We investigated the relation between patients'' diabetes-related knowledge (DRK) and measurements of risk factor control and cardiac outcomes. Two hundred patients who had diabetes mellitus and ACS and were admitted to a university hospital were enrolled over a 9-month period. At enrollment, clinical and demographic data were recorded, and each patient completed a previously validated DRK assessment. Clinical outcomes data were obtained 6 months after enrollment. Years of education and DRK assessment score were moderately correlated (r = 0.496, p <0.0001). Glycosylated hemoglobin, low-density lipoprotein cholesterol, and body mass index showed no correlation with DRK assessment score (r = −0.045, −0.005, and 0.175, respectively), even after multivariable adjustment for differences in age, race, insulin requirement, duration of diabetes, and years of education. Rates of 6-month death (6.2% vs 9.7%) and death or myocardial infarction (15.5% vs 19.4%) were not significantly different between groups of patients stratified by DRK assessment scores (high vs low scoring groups). Thus, among patients who have diabetes and ACS, there is a moderate correlation between years of education and DRK. We found no correlation between DRK and measurements of risk factor control or 6-month clinical outcomes. New strategies must be developed to translate understanding of disease into better risk factor modification among patients who have diabetes and ACS. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
80. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis
- Author
-
Deo, Rajat, Khera, Amit, McGuire, Darren K., Murphy, Sabina A., de P. Meo Neto, Januario, Morrow, David A., and de Lemos, James A.
- Subjects
- *
TOMOGRAPHY , *CORONARY arteries , *HEART blood-vessels , *MEDICAL radiography - Abstract
We sought to evaluate the association between plasma levels of monocyte chemoattractant protein (MCP)-1 and the risk for subclinical atherosclerosis.Monocyte chemoattractant protein is a chemokine that recruits monocytes into the developing atheroma and may contribute to atherosclerotic disease development and progression. Plasma levels of MCP-1 are independently associated with prognosis in patients with acute coronary syndromes, but few population-based data are available from subjects in earlier stages of atherosclerosis.In the Dallas Heart Study, a population-based probability sample of adults in Dallas County ≤65 years old, plasma levels of MCP-1 were measured in 3,499 subjects and correlated with traditional cardiovascular risk factors, high-sensitivityC-reactive protein (hs-CRP), and coronary artery calcium (CAC) measured by electron beam computed tomography.Higher MCP-1 levels were associated with older age, white race, family history of premature coronary disease, smoking, hypertension, diabetes, hypercholesterolemia, and higher levels of hs-CRP (p < 0.01 for each). Similar associations were observed between MCP-1 and risk factors in the subgroup of participants without detectable CAC. Compared with the subjects in the lowest quartile of MCP-1, the odds of prevalent CAC (CAC score ≥10) for subjects in the second, third, and fourth quartiles were 1.30 (95% confidence interval [CI] 0.99 to 1.73), 1.60 (95% CI 1.22 to 2.11), and 2.02 (95% CI 1.54 to 2.63), respectively. The association between MCP-1 and CAC remained significant when adjusted for traditional cardiovascular risk factors, but not when further adjusted for age.In a large population-based sample, plasma levels of MCP-1 were associated with traditional risk factors for atherosclerosis, supporting the hypothesis that MCP-1 may mediate some of the atherogenic effects of these risk factors. These findings support the potential role of MCP-1 as a biomarker target for drug development. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
81. African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study
- Author
-
Jain, Tulika, Peshock, Ronald, McGuire, Darren K., Willett, DuWayne, Yu, Zhoazia, Vega, Gloria L., Guerra, Rudy, Hobbs, Helen H., and Grundy, Scott M.
- Subjects
- *
HEART diseases , *MORTALITY , *ADULTS , *CORONARY disease - Abstract
We sought to compare the prevalence of coronary atherosclerosis in a cohort of middle-age African American (black) and non-Hispanic Caucasian (white) men and women from a population-based probability sample.Blacks have a higher mortality from coronary heart disease (CHD) than whites, particularly among younger individuals, and yet several studies have reported that coronary atherosclerosis is less prevalent in blacks than in whites. Data from population-based samples comparing coronary atherosclerotic burden between blacks and whites are limited.The prevalence of coronary atherosclerosis in middle-aged blacks and whites was determined using coronary calcium measured by electron beam computed tomography in 1,289 men and women from a population-based probability sample from Dallas, Texas.The population estimates of the frequency of a positive scan for coronary artery calcium were not statistically different between black and white men (37% vs. 41%, p = 0.36) or between black and white women (29% vs. 23%, p = 0.21). Although the prevalence of most of the coronary risk factors varied significantly between blacks and whites, mean Framingham coronary risk factor scores were identical in black and white men (10 ± 4) but significantly higher in black women (13 ± 4) than in white women (12 ± 4).Blacks in the general population have a prevalence of coronary atherosclerosis similar to whites. Factors other than coronary atherosclerotic burden, which are not reflected in the Framingham risk score, contribute significantly to the higher CHD mortality rate in blacks. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
82. In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction.
- Author
-
Rao, Vishal N., Murray, Evan, Butler, Javed, Cooper, Lauren B., Cox, Zachary L., Fiuzat, Mona, Green, Jennifer B., Lindenfeld, JoAnn, McGuire, Darren K., Nassif, Michael E., O'Brien, Cara, Pagidipati, Neha, Sharma, Kavita, Vaduganathan, Muthiah, Vardeny, Orly, Fonarow, Gregg C., Mentz, Robert J., and Greene, Stephen J.
- Subjects
- *
VENTRICULAR ejection fraction , *HEART failure , *MEDICAL personnel , *BLOOD pressure , *DRUGS , *GASTRIC inhibitory polypeptide , *ACE inhibitors - Abstract
Sodium-glucose cotransporter-2 inhibitor therapy is well suited for initiation during the heart failure hospitalization, owing to clinical benefits that accrue rapidly within days to weeks, a strong safety and tolerability profile, minimal to no effects on blood pressure, and no excess risk of adverse kidney events. There is no evidence to suggest that deferring initiation to the outpatient setting accomplishes anything beneficial. Instead, there is compelling evidence that deferring in-hospital initiation exposes patients to excess risk of early postdischarge clinical worsening and death. Lessons from other heart failure with reduced ejection fraction therapies highlight that deferring initiation of guideline-recommended medications to the U.S. outpatient setting carries a >75% chance they will not be initiated within the next year. Recognizing that 1 in 4 patients hospitalized for worsening heart failure die or are readmitted within 30 days, clinicians should embrace the in-hospital period as an optimal time to initiate sodium-glucose cotransporter-2 inhibitor therapy and treat this population with the urgency it deserves. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
83. Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults.
- Author
-
Segar, Matthew W., Khan, Muhammad Shahzeb, Patel, Kershaw V., Butler, Javed, Tang, W.H. Wilson, Vaduganathan, Muthiah, Lam, Carolyn S.P., Verma, Subodh, McGuire, Darren K., and Pandey, Ambarish
- Subjects
- *
PROGNOSIS , *CARDIOVASCULAR diseases , *CHRONIC kidney failure , *CARDIOMYOPATHIES , *HEART failure , *BLOOD sugar analysis , *GLOMERULAR filtration rate , *BIOLOGICAL models , *RESEARCH , *DIABETIC cardiomyopathy , *AGE distribution , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *TYPE 2 diabetes , *COMPARATIVE studies , *DISEASE prevalence , *BODY mass index , *LONGITUDINAL method - Abstract
Background: Diabetes is associated with abnormalities in cardiac remodeling and high risk of heart failure (HF).Objectives: The purpose of this study was to evaluate the prevalence and prognostic implications of diabetes with cardiomyopathy (DbCM) among community-dwelling individuals.Methods: Adults without prevalent cardiovascular disease or HF were pooled from 3 cohort studies (ARIC [Atherosclerosis Risk In Communities], CHS [Cardiovascular Health Study], CRIC [Chronic Renal Insufficiency Cohort]). Among participants with diabetes, DbCM was defined using different definitions: 1) least restrictive: ≥1 echocardiographic abnormality (left atrial enlargement, left ventricle hypertrophy, diastolic dysfunction); 2) intermediate restrictive: ≥2 echocardiographic abnormalities; and 3) most restrictive: elevated N-terminal pro-B-type natriuretic peptide levels (>125 in normal/overweight or >100 pg/mL in obese) plus ≥2 echocardiographic abnormalities. Adjusted Fine-Gray models were used to evaluate the risk of HF.Results: Among individuals with diabetes (2,900 of 10,208 included), the prevalence of DbCM ranged from 67.0% to 11.7% in the least and most restrictive criteria, respectively. Higher fasting glucose, body mass index, and age as well as worse kidney function were associated with higher risk of DbCM. The 5-year incidence of HF among participants with DbCM ranged from 8.4%-12.8% in the least and most restrictive definitions, respectively. Compared with euglycemia, DbCM was significantly associated with higher risk of incident HF with the highest risk observed for the most restrictive definition of DbCM (HR: 2.55 [95% CI: 1.69-3.86]; least restrictive criteria HR: 1.99 [95% CI: 1.50-2.65]). A similar pattern of results was observed across cohort studies, across sex and race subgroups, and among participants without hypertension or obesity.Conclusions: Regardless of the criteria used to define cardiomyopathy, DbCM identifies a high-risk subgroup for developing HF. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
84. PERSISTENCE AND DISCONTINUATION OF SGLT-2I AND GLP-1RA AMONG PERSONS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE TREATED IN US CARDIOLOGY CLINICS: INSIGHTS FROM THE COORDINATE-DIABETES TRIAL.
- Author
-
Nelson, Adam J., Pagidipati, Neha J., Kaltenbach, Lisa, Green, Jennifer, Lopes, Renato D., Al-Khalidi, Hussein, Aroda, Vanita, Cavender, Matthew Aaron, Kirk, Julienne, Lingvay, Ildiko, Magwire, Melissa, Pop-Busui, Rodica, Richardson, Caroline Regina, Leyva, Monica, Webb, Laura, Pandey, Ambarish, Washington, Alana, Gaynor, Tanya, Pak, Jonathan, and McGuire, Darren K.
- Subjects
- *
TYPE 2 diabetes , *CARDIOVASCULAR diseases , *CARDIOLOGY - Published
- 2024
- Full Text
- View/download PDF
85. RELATIONSHIP BETWEEN INFLAMMATORY BIOMARKERS AND OUTCOMES: AN ANALYSIS FROM DEFINE-HF.
- Author
-
Sherrod, Charles, Sauer, Andrew, Patel, Shachi, Windsor, Sheryl, Nassif, Michael, Husain, Mansoor, Inzucchi, Silvio E., McGuire, Darren K., Pitt, Bertram, Scirica, Benjamin M., Austin, Bethany Anne, Umpierrez, Guillermo, Margulies, Kenneth B., Lanfear, David E., and Kosiborod, Mikhail
- Subjects
- *
BIOMARKERS - Published
- 2024
- Full Text
- View/download PDF
86. SOLUBLE SUPPRESSION OF TUMORIGENICITY 2 (SST2) AND CARDIOVASCULAR OUTCOMES IN PERSONS WITH TYPE 2 DIABETES MELLITUS RANDOMIZED TO DAPAGLIFLOZIN OR PLACEBO: ANALYSES FROM THE DECLARE-TIMI 58 TRIAL.
- Author
-
Haller, Paul, Wiviott, Stephen, Jarolim, Petr, Goodrich, Erica L., Bhatt, Deepak L., Gause-Nilsson, Ingrid, Leiter, Lawrence A., McGuire, Darren K., Raz, Itamar, Wilding, John, Sabatine, Marc Steven, and Morrow, David A.
- Subjects
- *
TYPE 2 diabetes , *DAPAGLIFLOZIN , *PLACEBOS - Published
- 2024
- Full Text
- View/download PDF
87. METABOLIC EFFECTS OF DAPAGLIFLOZIN IN HEART FAILURE ACROSS THE SPECTRUM OF EJECTION FRACTION.
- Author
-
Selvaraj, Senthil, Patel, Shachi, Sauer, Andrew, McGarrah, Robert, Jones, Philip, Kwee, Lydia, Windsor, Sheryl L., Ilkayeva, Olga, Muehlbauer, Michael, Newgard, Christopher B., Borlaug, Barry, Kitzman, Dalane W., Shah, Sanjiv Jayendra, Margulies, Kenneth B., Husain, Mansoor, Inzucchi, Silvio E., McGuire, Darren K., Lanfear, David E., Javaheri, Ali, and Umpierrez, Guillermo
- Subjects
- *
VENTRICULAR ejection fraction , *HEART failure , *DAPAGLIFLOZIN - Published
- 2024
- Full Text
- View/download PDF
88. Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial.
- Author
-
Cavallari, Ilaria, Bhatt, Deepak L., Steg, Ph. Gabriel, Leiter, Lawrence A., McGuire, Darren K., Mosenzon, Ofri, Im, Kyungah, Raz, Itamar, Braunwald, Eugene, and Scirica, Benjamin M.
- Subjects
- *
DIABETES , *TYPE 2 diabetes - Published
- 2021
- Full Text
- View/download PDF
89. Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.
- Author
-
Guimarães, Patrícia O., Peterson, Eric D., Stevens, Susanna R., Lokhnygina, Yuliya, Green, Jennifer B., McGuire, Darren K., Holman, Rury R., and Lopes, Renato D.
- Subjects
- *
ATRIAL fibrillation , *THERAPEUTICS , *TYPE 2 diabetes , *STROKE , *CLINICAL trial registries , *PROPORTIONAL hazards models , *PERIPHERAL vascular diseases - Abstract
We investigated the use of different antithrombotic therapies at baseline among patients with a history of atrial fibrillation (AF), type 2 diabetes, and established atherosclerotic cardiovascular disease (ASCVD) enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). TECOS participants with a history of AF were stratified by CHA 2 DS 2 -VASc score and their antithrombotic use evaluated. Cox proportional hazards models were employed to explore possible associations between history of AF and prespecified clinical outcomes after adjusting for key baseline characteristics. Of the 14,671 TECOS participants, 1167 (8%) had a history of AF, of whom 51.6% were using vitamin K antagonists (VKA); 31.2% used VKA alone, 16.9% used aspirin plus VKA, 1.8% used clopidogrel plus VKA, and 1.7% used aspirin and clopidogrel plus VKA. Aspirin was used by 56.8%: 30.9% used aspirin alone and 7.3% aspirin plus clopidogrel. Clopidogrel alone was used by 2.9%, and 7.3% were not using any antithrombotic medication. Participants with a history of AF had a higher risk of cardiovascular events, including hospitalization for heart failure and all-cause mortality, than those without AF. White, older men with prior myocardial infarction, heart failure, peripheral artery disease, or prior stroke were more likely to develop new-onset AF than others without these characteristics. Almost half of high-risk AF patients with diabetes and established ASCVD in TECOS were not treated with anticoagulation therapy despite clear guideline recommendations for such therapy, highlighting the challenge and potential for clinical improvements in managing these patients in clinical practice. Clinical Trial Registration : URL: http://www.clinicaltrials.gov. Unique identifier: NCT00790205. • Afib and type 2 diabetes are associated with adverse cardiovascular outcomes. • We examined OAC use by TECOS patients with Afib, ASCVD, and type 2 diabetes. • OAC use by these high-risk patients is much less than guideline recommendations. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
90. Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.
- Author
-
Greene, Stephen J., Vaduganathan, Muthiah, Khan, Muhammad Shahzeb, Bakris, George L., Weir, Matthew R., Seltzer, Jonathan H., Sattar, Naveed, McGuire, Darren K., Januzzi, James L., Stockbridge, Norman, and Butler, Javed
- Subjects
- *
HEART failure , *HEART diseases , *DRUG approval , *CARDIOVASCULAR agents - Abstract
Despite multiple examples of glucose-lowering therapies affecting heart failure (HF) risk, ascertainment of HF data in cardiovascular outcome trials of these medications has not been systematically characterized. In this review, large (n >1,000) published phase III and IV cardiovascular outcome trials evaluating glucose-lowering therapies through June 2017 were identified. Data were abstracted from publications, U.S. Food and Drug Administration advisory committee records, and U.S. Food and Drug Administration labeling documents. Overall, 21 trials including 152,737 patients were evaluated. Rates and definitions of baseline HF and incident HF were inconsistently provided. Baseline ejection fraction data were provided in 3 studies but not specific to patients with HF. No trial reported functional class, ejection fraction, or HF therapy at the time of incident HF diagnosis. HF hospitalization data were available in 15 trials, but only 2 included HF-related events within the primary composite endpoint. This systematic review highlights gaps in HF data capture within cardiovascular outcome trials of glucose-lowering therapies and outlines rationale and strategies for improving HF characterization. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
91. RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58.
- Author
-
Small, Andre M., Berg, David, Raz, Itamar, Goodrich, Erica L., Moura, Filipe, Mosenzon, Ofri, Cahn, Avivit, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John, Gause-Nilsson, Ingrid, Sabatine, Marc Steven, Morrow, David A., and Wiviott, Stephen D.
- Subjects
- *
CYSTATIN C , *EPIDERMAL growth factor receptors , *KIDNEYS - Published
- 2023
- Full Text
- View/download PDF
92. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases.
- Author
-
Handelsman, Yehuda, Butler, Javed, Bakris, George L., DeFronzo, Ralph A., Fonarow, Gregg C., Green, Jennifer B., Grunberger, George, Januzzi, James L., Klein, Samuel, Kushner, Pamela R., McGuire, Darren K., Michos, Erin D., Morales, Javier, Pratley, Richard E., Weir, Matthew R., Wright, Eugene, and Fonseca, Vivian A.
- Abstract
Increasing rates of obesity and diabetes have driven corresponding increases in related cardiorenal and metabolic diseases. In many patients, these conditions occur together, further increasing morbidity and mortality risks to the individual. Yet all too often, the risk factors for these disorders are not addressed promptly in clinical practice, leading to irreversible pathologic progression. To address this gap, we convened a Task Force of experts in cardiology, nephrology, endocrinology, and primary care to develop recommendations for early identification and intervention in obesity, diabetes, and other cardiorenal and metabolic diseases. The recommendations include screening and diagnosis, early interventions with lifestyle, and when and how to implement medical therapies. These recommendations are organized into primary and secondary prevention along the continuum from obesity through the metabolic syndrome, prediabetes, diabetes, hypertension, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), atherosclerotic cardiovascular disease (ASCVD) and atrial fibrillation, chronic kidney disease (CKD), and heart failure (HF). The goal of early and intensive intervention is primary prevention of comorbidities or secondary prevention to decrease further worsening of disease and reduce morbidity and mortality. These efforts will reduce clinical inertia and may improve patients' well-being and adherence. • Diabetes, obesity and cardiorenal/metabolic disease often occur in the same patient. • Suboptimal metabolic control has not improved in past 20 years despite new medications. • Traditional, stepwise treatment often leads to inertia and morbidity and mortality. • Early intensive combination intervention can prevent disease progression and events. • Recommendations cover early intervention in both primary and secondary prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
93. Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study.
- Author
-
Tientcheu, Danielle, Ayers, Colby, Das, Sandeep R., McGuire, Darren K., de Lemos, James A., Khera, Amit, Kaplan, Norman, Victor, Ronald, and Vongpatanasin, Wanpen
- Subjects
- *
MASKED hypertension , *CARDIOVASCULAR diseases , *ORGANS (Anatomy) , *MAGNETIC resonance imaging , *COHORT analysis , *ALBUMINS , *CREATININE , *CYSTATINS , *WOUNDS & injuries , *ANTIHYPERTENSIVE agents , *BLOOD pressure , *BLOOD pressure measurement , *ETHNIC groups , *HYPERTENSION , *LONGITUDINAL method , *HEALTH outcome assessment , *PROGNOSIS , *RESEARCH funding , *DISEASE prevalence , *DISEASE complications - Abstract
Background: Multiple epidemiological studies from Europe and Asia have demonstrated increased cardiovascular risks associated with isolated elevation of home blood pressure (BP) or masked hypertension (MH). Previous studies have not addressed cardiovascular outcomes associated with MH and white-coat hypertension (WCH) in the general population in the United States.Objectives: The goal of this study was to determine hypertensive target organ damage and adverse cardiovascular outcomes associated with WCH (high clinic BP, ≥140/90 mm Hg; normal home BP, <135/85 mm Hg), MH (high home BP, ≥135/85 mm Hg; normal clinic BP, <140/90 mm Hg), and sustained hypertension (high home and clinic BP) in the DHS (Dallas Heart Study), a large, multiethnic, probability-based population cohort.Methods: Associations among WCH, MH, sustained hypertension, and aortic pulsed wave velocity by magnetic resonance imaging; urinary albumin-to-creatinine ratio; and cystatin C were evaluated at study baseline. Then, associations between WCH and MH with incident cardiovascular outcomes (coronary heart disease, stroke, atrial fibrillation, heart failure, and cardiovascular death) over a median follow-up period of 9 years were assessed.Results: The study cohort comprised 3,027 subjects (50% African Americans). The sample-weighted prevalence rates of WCH and MH were 3.3% and 17.8%, respectively. Both WCH and MH were independently associated with increased aortic pulsed wave velocity, cystatin C, and urinary albumin-to-creatinine ratio. Both WCH (adjusted hazard ratio: 2.09; 95% confidence interval: 1.05 to 4.15) and MH (adjusted hazard ratio: 2.03; 95% confidence interval: 1.36 to 3.03) were independently associated with higher cardiovascular events compared with the normotensive group, even after adjustment for traditional cardiovascular risk factors.Conclusions: In a multiethnic U.S. population, both WCH and MH were independently associated with increased aortic stiffness, renal injury, and incident cardiovascular events. Because MH is common and associated with an adverse cardiovascular profile, home BP monitoring should be routinely performed among U.S. adults. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
94. Relation of Black Race Between High Density Lipoprotein Cholesterol Content, High Density Lipoprotein Particles and Coronary Events (from the Dallas Heart Study).
- Author
-
Chandra, Alvin, Neeland, Ian J., Das, Sandeep R., Khera, Amit, Turer, Asian T., Ayers, Colby R., McGuire, Darren K., and Rohatgi, Anand
- Subjects
- *
BLACK race , *HIGH density lipoproteins , *CORONARY disease , *BLOOD cholesterol , *ATHEROSCLEROSIS , *MAGNETIC resonance imaging - Abstract
Therapies targeting high-density lipoprotein cholesterol content (HDL-C) have not improved coronary heart disease (CHD) outcomes. High-density lipoprotein particle concentration (HDL-P) may better predict CHD. However, the impact of race/ethnicity on the relations between HDL-P and subclinical atherosclerosis and incident CHD events has not been described. Participants from the Dallas Heart Study (DHS), a multiethnic, probabilitybased, population cohort of Dallas County adults, underwent the following baseline measurements: HDL-C, HDL-P by nuclear magnetic resonance imaging, and coronary artery calcium by electron-beam computed tomography. Participants were followed for a median of 9.3 years for incident CHD events (composite of first myocardial infarction, stroke, coronary revascularization, or cardiovascular death). The study comprised 1,977 participants free of CHD (51% women, 46% black). In adjusted models, HDL-C was not associated with prevalent coronary artery calcium (p = 0.13) or incident CHD overall (hazard ratio [HR] per 1 SD 0.89, 95% confidence interval [CI] 0.76 to 1.05). However, HDL-C was inversely associated with incident CHD among nonblack (adjusted HR per 1 SD 0.67, 95% CI 0.46 to 0.97) but not black participants (HR 0.94,95% CI 0.78 to 1.13, Pinteraction = 0.05). Conversely, HDL-P, adjusted for risk factors and HDL-C, was inversely associated with prevalent coronary artery calcium (p = 0.009) and with incident CHD overall (adjusted HR per 1 SD 0.73, 95% CI 0.62 to 0.86), with no interaction by black race/ethnicity (Pinteraction = 0.57). In conclusion, in contrast to HDL-C, the inverse relation between HDL-P and incident CHD events is consistent across ethnicities. These findings suggest that HDL-P is superior to HDL-C in predicting prevalent atherosclerosis as well as incident CHD events across a diverse population and should be considered as a therapeutic target. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
95. The Relationship of Body Mass and Fat Distribution With Incident Hypertension: Observations From the Dallas Heart Study.
- Author
-
Chandra, Alvin, Neeland, Ian J., Berry, Jarett D., Ayers, Colby R., Rohatgi, Anand, Das, Sandeep R., Khera, Amit, McGuire, Darren K., de Lemos, James A., and Turer, Aslan T.
- Subjects
- *
BODY mass index , *SYSTOLIC blood pressure , *OBESITY , *HYPERTENSION , *ADIPOSE tissues , *MAGNETIC resonance imaging , *MULTIVARIABLE testing - Abstract
Background Obesity has been linked to the development of hypertension, but whether total adiposity or site-specific fat accumulation underpins this relationship is unclear. Objectives This study sought to determine the relationship between adipose tissue distribution and incident hypertension. Methods Normotensive participants enrolled in the Dallas Heart Study were followed for a median of 7 years for the development of hypertension (systolic blood pressure [SBP] ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or initiation of blood pressure medications). Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) was quantified by magnetic resonance imaging and proton-spectroscopic imaging, and lower body fat (LBF) was imaged by dual-energy x-ray absorptiometry. Multivariable relative risk regression was performed to test the association between individual fat depots and incident hypertension, adjusting for age, sex, race/ethnicity, diabetes, smoking, SBP, and body mass index (BMI). Results Among 903 participants (median age, 40 years; 57% women; 60% nonwhite; median BMI 27.5 kg/m 2 ), 230 (25%) developed incident hypertension. In multivariable analyses, higher BMI was significantly associated with incident hypertension (relative risk: 1.24; 95% confidence interval: 1.12 to 1.36, per 1-SD increase). However, when VAT, SAT, and LBF were added to the model, only VAT remained independently associated with incident hypertension (relative risk: 1.22; 95% confidence interval: 1.06 to 1.39, per 1-SD increase). Conclusions Increased visceral adiposity, but not total or subcutaneous adiposity, was robustly associated with incident hypertension. Additional studies will be needed to elucidate the mechanisms behind this association. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
96. Patterns and Predictors of Intensive Statin Therapy Among Patients With Diabetes Mellitus After Acute Myocardial Infarction.
- Author
-
Abdallah, Mouin S., Kosiborod, Mikhail, Fengming Tang, Karrowni, Wassef Y., Maddox, Thomas M., McGuire, Darren K., Spertus, John A., and Arnold, Suzanne V.
- Subjects
- *
STATINS (Cardiovascular agents) , *TREATMENT of diabetes , *MYOCARDIAL infarction , *LOW density lipoproteins , *BLOOD cholesterol , *TREATMENT of acute coronary syndrome , *PATIENTS - Abstract
Intensive statin therapy is a central component of secondary prevention after acute myocardial infarction (AMI), particularly among high-risk patients, such as those with diabetes mellitus (DM). However, the frequency and predictors of intensive statin therapy use after AMI among patients withDMhave not been described. We examined patterns of intensive statin therapy use (defined as a statin with expected low-density lipoprotein cholesterol lowering of >50%) at discharge among patientswithAMIwithknownDMenrolled in a 24-siteUSregistry. Predictors of intensive statin therapy use were evaluated using multivariable hierarchical Poisson regression models. Among 1,300 patients with DM after AMI, 22% were prescribed intensive statin therapy at hospital discharge. Inmultivariablemodels, ST-elevationAMI (risk ratio [RR] 1.48, 95% confidence interval [CI] 1.29 to 1.70), insurance for medications (RR 1.28, 95% CI 1.00 to 1.63), and higher low-density lipoprotein cholesterol levels (RR1.05 per 1mg/dl, 95%CI 1.02 to 1.07) were independent predictors of intensive statin therapy, whereas higher Global Registry of Acute Coronary Events scores were associated with lower rates of intensive statin therapy (RR0.94 per 10 points, 95%CI 0.91 to 0.98). In conclusion, only 1 in 5 patients withDM was prescribed intensive statin therapy at discharge after an AMI. Predictors of intensive statin therapy use suggest important opportunities to improve quality of care in this patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
97. Age- and Sex-Dependent Upper Reference Limits for the High-Sensitivity Cardiac Troponin T Assay.
- Author
-
Gore, M. Odette, Seliger, Stephen L., deFilippi, Christopher R., Nambi, Vijay, Christenson, Robert H., Hashim, Ibrahim A., Hoogeveen, Ron C., Ayers, Colby R., Sun, Wensheng, McGuire, Darren K., Ballantyne, Christie M., and de Lemos, James A.
- Subjects
- *
TROPONIN , *NATRIURETIC peptides , *CARDIOVASCULAR diseases , *KIDNEY diseases , *DATA analysis , *COHORT analysis ,MYOCARDIAL infarction diagnosis - Abstract
Objectives: The study sought to determine the 99th percentile upper reference limit for the high-sensitivity cardiac troponin T assay (hs-cTnT) in 3 large independent cohorts. Background: The presently recommended 14 ng/l cut point for the diagnosis of myocardial infarction using the hs-cTnT assay was derived from small studies of presumably healthy individuals, with relatively little phenotypic characterization. Methods: Data were included from 3 well-characterized population-based studies: the Dallas Heart Study (DHS), the Atherosclerosis Risk in Communities (ARIC) Study, and the Cardiovascular Health Study (CHS). Within each cohort, reference subcohorts were defined excluding individuals with recent hospitalization, overt cardiovascular disease, and kidney disease (subcohort 1), and further excluding those with subclinical structural heart disease (subcohort 2). Data were analyzed stratified by age, sex, and race. Results: The 99th percentile values for the hs-cTnT assay in DHS, ARIC, and CHS were 18, 22, and 36 ng/l (subcohort 1) and 14, 21, and 28 ng/l (subcohort 2), respectively. These differences in 99th percentile values paralleled age differences across cohorts. Analyses within sex/age strata yielded similar results between cohorts. Within each cohort, 99th percentile values increased with age and were higher in men. More than 10% of men 65 to 74 years of age with no cardiovascular disease in our study had cardiac troponin T values above the current myocardial infarction threshold. Conclusions: Use of a uniform 14 ng/l cutoff for the hs-cTnT assay may lead to over-diagnosis of myocardial infarction, particularly in men and the elderly. Clinical validation is needed of new age- and sex-specific cutoff values for this assay. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
98. FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58.
- Author
-
Berg, David, Wiviott, Stephen D., Raz, Itamar, Jarolim, Petr, Goodrich, Erica L., Mosenzon, Ofri, Cahn, Avivit, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John PH, Gause-Nilsson, Ingrid, Hammarstedt, Ann, Oscarsson, Jan, Sabatine, Marc Steven, and Morrow, David A.
- Subjects
- *
TYPE 2 diabetes , *FIBROBLASTS , *DAPAGLIFLOZIN - Published
- 2022
- Full Text
- View/download PDF
99. U.S. PATTERNS OF DRUG UTILIZATION AND PRESCRIPTION FILLS FOR PROVEN CARDIOPROTECTIVE ANTI-HYPERGLYCEMIC AGENTS.
- Author
-
Nargesi, Arash Aghajani, Clark, Callahan, Liu, Mengni, Chen, Lian, Reddy, Abraham, Amodeo, Samuel, Oikonomou, Evangelos K., Suchard, Marc, Lipska, Kasia, McGuire, Darren K., Lin, Zhenqiu, Inzucchi, Silvio E., Krumholz, Harlan M., and Khera, Rohan
- Subjects
- *
HYPOGLYCEMIC agents , *DRUG utilization , *CARDIOTONIC agents , *DRUGS - Published
- 2022
- Full Text
- View/download PDF
100. The Reliability and Prognosis of In-Hospital Diagnosis of Metabolic Syndrome in the Setting of Acute Myocardial Infarction.
- Author
-
Arnold, Suzanne V., Lipska, Kasia J., Li, Yan, Goyal, Abhinav, Maddox, Thomas M., McGuire, Darren K., Spertus, John A., and Kosiborod, Mikhail
- Subjects
- *
CORONARY disease , *MYOCARDIAL infarction , *METABOLIC syndrome , *HOSPITAL care , *COHORT analysis , *HEALTH outcome assessment - Abstract
Objectives: This study sought to examine the reliability and prognostic importance of an in-hospital diagnosis of metabolic syndrome (MetS) in the setting of acute myocardial infarction (AMI). Background: Because the factors that comprise MetS are believed to be altered in the setting of AMI, the diagnosis of MetS during AMI hospitalization and its prognostic significance have not been studied. Methods: We assessed patients within a multicenter registry for metabolic factors at baseline and 1 month post-AMI and followed them for mortality and rehospitalizations. The accuracy of an inpatient diagnosis of MetS was calculated using a 1-month follow-up as the gold standard. Patients were categorized based on MetS diagnosis at baseline and 1 month, and the combined endpoint of death or rehospitalization over 12 months was compared between groups. Results: Of the 1,129 patients hospitalized for AMI, diagnostic criteria for MetS were met by 69% during AMI hospitalization and 63% at 1 month. Inpatient MetS diagnosis had a sensitivity and specificity for outpatient diagnosis of 87% and 61%, respectively, and was associated with an 11 times increased odds of an outpatient diagnosis (C-index 0.74). Compared with patients without MetS during hospitalization and follow-up, patients classified as MetS during AMI but not follow-up had worse outcomes, whereas those classified MetS at follow-up had the worst outcomes (rates for combined endpoint 27% vs. 37% vs. 38%; log-rank p = 0.01). Conclusions: In a large cohort of patients with AMI, the diagnosis of MetS is common and can be made with reasonable accuracy during AMI. MetS is associated with poor outcomes, regardless of whether the diagnosis is confirmed during subsequent outpatient visit, and identifies a high-risk cohort of patients that may benefit from more aggressive risk factor modification. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.